Clinical trials: Glaucoma Secondary
Primary Open Angle Glaucoma (POAG)
iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.
- Trial name
- NCT03478293
- Testing
- iStent inject surgery
- Where
- Brazil
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle
A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent Supra
Prospective Evaluation of Open-Angle Glaucoma Subjects treated with two second generation iStents and one iStent Supra
- Trial name
- GCF-041 (NCT03255798)
- Testing
- G2 and G3
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Glaukos Corporation
Glaucoma,Open-Angle, Ocular Hypertension
Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®
The primary objective is to evaluate the Intraocular pressure reducing effect of Xalatan over 3 months. The secondary objective is to study the other efficacy parameters during treatment for 3 months
- Trial name
- NCT00486252
- Testing
- Observational
- Volunteers
- 996 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma
Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive Medication
This study objective is to evaluate the intraocular pressure (IOP) lowering effect of two trabecular micro-bypass stents (iStent inject) in eyes of subjects with primary open-angle glaucoma on one topical hypotensive medication
- Trial name
- NCT02868190
- Testing
- Two trabecular micro-bypass stents (iStent inject)
- Where
- Armenia
- Volunteers
- 57 people
- Sponsor
- Glaukos Corporation
Glaucoma
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Trial name
- NCT07495852
- Testing
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%
- Where
- United States
- Volunteers
- 510 people
- Sponsor
- Glaukos Corporation
Glaucoma
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Trial name
- NCT07075718
- Testing
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Glaukos Corporation